Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study (CD4-01)

NCT00895206 Phase 4 COMPLETED

This study is an open, randomised trial in which one group of patients (control) will receive the golden standard therapy and the other group (treatment) will receive individually adapted immunosuppression.

Details

Lead sponsor	University Hospital, Ghent
Phase	Phase 4
Status	COMPLETED
Enrolment	128
Start date	2009-05
Completion	2016-10

Conditions

• Kidney Transplantation

Interventions

• individual adapted immunosuppression
• golden standard therapy

Primary outcomes

• Graft function as measured by Cr EDTA AUC — at 1 year

Countries

Belgium